Ionis Pharmaceuticals, Inc. (IONS)
Ionis Pharmaceuticals: Bull Run Can Continue As Major Catalysts Approach
Ionis Pharmaceuticals remains a Buy, with a compelling bull case despite a >125% 12-month share price increase. IONS is transitioning from niche indications to multi-billion-dollar markets, leveraging key partnerships and upcoming product launches. Projected 2030 revenues exceed $5bn, driven by Tryngolza, Dawnzera, and significant royalty streams from eplontersen, bepiroversen, and pelacarsen.
Ionis Pharmaceuticals Eyes Big Year With TRYNGOLZA Decision, 5 Phase 3 Readouts
Ionis Pharmaceuticals NASDAQ: IONS highlighted a busy slate of regulatory decisions, clinical readouts and partnered programs during a presentation at RBC Capital Markets' Global Healthcare Conference, with Chief Development Officer Holly Kordasiewicz saying the company is moving from recent launches into a broader commercial and late-stage development phase.
Ionis Pharmaceuticals, Inc. (IONS) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
Ionis Pharmaceuticals, Inc. (IONS) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
Ionis Pharmaceuticals Touts $3B TRYNGOLZA Opportunity, Pipeline Readouts at Conference
Executives at a healthcare investor event outlined commercial launch plans, pipeline readouts and market-development priorities across several biotechnology franchises, with discussion spanning Ionis Pharmaceuticals NASDAQ: IONS products including TRYNGOLZA, DAWNZERA and WAINUA, as well as Neurocrine Biosciences' commercial and pipeline strategy. Get Ionis Pharmaceuticals alerts:Sign UpIonis Highlights TRYNGOLZA Opportunity in Severe Hypertriglyceridemia Todd Tushla, vice president of investor relations, said Ionis is preparing for a potential June 30 FDA action date for olezarsen in severe hypertriglyceridemia, or sHTG.
Ionis Pharmaceuticals, Inc. (IONS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Ionis Pharmaceuticals, Inc. (IONS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Ionis Pharmaceuticals, Inc. (IONS) Q1 2026 Earnings Call Transcript
Ionis Pharmaceuticals, Inc. (IONS) Q1 2026 Earnings Call Transcript
Compared to Estimates, Ionis Pharmaceuticals (IONS) Q1 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Ionis Pharmaceuticals (IONS) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Ionis Pharmaceuticals (IONS) Reports Q1 Loss, Tops Revenue Estimates
Ionis Pharmaceuticals (IONS) came out with a quarterly loss of $0.3 per share versus the Zacks Consensus Estimate of a loss of $0.85. This compares to a loss of $0.75 per share a year ago.
Why Is Ionis Pharmaceuticals (IONS) Down 7.9% Since Last Earnings Report?
Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock?
FDA Grants Priority Tag to Ionis' NDA for Alexander Disease Drug
IONS wins FDA priority review for zilganersen in rare Alexander disease, with a Sept. 22, 2026, decision date backed by strong phase III data.
Ionis Pharmaceuticals, Inc. (IONS) Presents at Stifel 2026 Virtual CNS Forum Transcript
Ionis Pharmaceuticals, Inc. (IONS) Presents at Stifel 2026 Virtual CNS Forum Transcript
Algert Global LLC Grows Position in Ionis Pharmaceuticals, Inc. $IONS
Algert Global LLC grew its position in Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) by 562.3% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 252,281 shares of the company's stock after purchasing an additional 214,191 shares during the period. Algert Global LLC
